DYNAVAX TECHNOLOGIES

DVAX
Delayed Quote. Delayed  - 01/27 04:00:00 pm
6.14USD -0.49%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Number of employees : 231 people.
Sales per Business
2019
USD
(in Million)
%
Biopharmaceutical Products 34.6498.4%
Other 0.4321.2%
Collaboration 0.1430.4%
Sales per region
2019
USD
(in Million)
%
United States 35.22100%
Managers
Name Title
Ryan Spencer Chief Executive Officer & Director
David F. Novack President & Chief Operating Officer
Andrew A. F. Hack Chairman
Michael S. Ostrach Senior VP, Chief Financial & Business Officer
Robert Janssen Chief Medical Officer & SVP-Clinical Development
Peggy V. Phillips Independent Director
Francis R. Cano Independent Director
Daniel L. Kisner Independent Director
Natale S. Ricciardi Independent Director
Brent MacGregor Director
Shareholders
Name Equities %
SSgA Funds Management, Inc. 11,603,107 10.5%
Federated Global Investment Management Corp. 10,946,800 9.94%
Bain Capital Life Sciences LP 10,895,773 9.89%
The Vanguard Group, Inc. 4,905,699 4.45%
HealthCor Management LP 4,613,280 4.19%
Chicago Capital LLC 3,930,524 3.57%
BlackRock Fund Advisors 3,610,620 3.28%
PFM Health Sciences LP 2,936,990 2.67%
Redmile Group LLC 2,548,620 2.31%
RA Capital Management LP 2,365,912 2.15%
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
DYNAVAX TECHNOLOGIES CORPORATION37.98%680
GILEAD SCIENCES, INC.12.39%83 610
WUXI APPTEC CO., LTD.36.65%64 891
VERTEX PHARMACEUTICALS-4.69%61 795
REGENERON PHARMACEUTICALS6.72%57 427
BEIGENE, LTD.24.12%32 675
GENMAB A/S5.56%27 803
BIONTECH SE29.99%25 593
ARGENX SE0.00%14 614
HUALAN BIOLOGICAL ENGINEERING INC.16.79%13 990
MYOKARDIA, INC.0.00%11 993
NEUROCRINE BIOSCIENCES, INC.21.16%10 850
MIRATI THERAPEUTICS, INC.-11.53%10 249
ULTRAGENYX PHARMACEUTICAL INC.-1.64%9 260
DENALI THERAPEUTICS INC.-16.75%8 752
ASCENDIS PHARMA A/S-8.86%8 410
ARROWHEAD PHARMACEUTICALS, INC.0.12%8 338
FATE THERAPEUTICS, INC.-3.75%8 187
KODIAK SCIENCES INC.-8.64%7 349
SAREPTA THERAPEUTICS, INC.-46.92%7 311
ACCELERON PHARMA INC.-10.50%7 287